Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ-listed (WBA) US pharmacy giant with 8,700 stores going private via Sycamore Partners LBO in 2024; major restructuring after 70% stock decline, clinic write-downs, and dividend cuts.
Walgreens Boots Alliance (NASDAQ: WBA) is the largest US pharmacy chain and global pharmacy-led health and wellness company — operating approximately 8,700 Walgreens locations in the US alongside Boots pharmacies in the UK and other international markets, providing prescription medications, over-the-counter health products, beauty items, and health clinic services through the largest drugstore footprint in the US. WBA generated $147 billion in revenue in fiscal year 2024 and serves approximately 9 million customers daily, making it one of the most visited retail destinations in the US.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.